Autologous stem cell transplantation appears to enhance outcome in multiple myeloma patients. To improve upon these results, various groups have utilized tandem autografts, as well as used reduced-conditioning allogeneic stem cell transplantation. These two approaches, discussed herein, have been promising. Inherent patient selection, however, appears to play a role and much of the data have not yet been subjected to peer-review scrutiny. At present, these strategis remain investigational and cannot be considered the standardof-care for multiple myeloma patients. Bone Marrow Transplantation (2001) 28, 725-735.
High-dose cytotoxic therapy with autologous hematopoietic stem cell transplant in multiple myeloma patients improves event-free and overall survival rates compared to conventional therapy as shown in a randomized trial reported by the Inter Groupe Français du Myéloma (IFM 90). 1 In recent years, transplant-related mortality has been lowered dramatically to less than 1% and survival after autotransplant has been improved from a median of 30-36 months to 55-65 months. 2 Most myeloma specialists now consider autotransplant to be the standard of care for newly diagnosed multiple myeloma patients. Improvements upon this initial advance, however, have been more difficult. Some strategies include addition of thalidomide to induction therapy, 3, 4 dose escalation of melphalan 5, 6 or the use of radio-isotopes to the transplant preparative regimen. 7, 8 Other approaches include use of post-transplant therapies such as immunotherapy (alpha interferon, dendritic cell therapy, vaccination with idiotype-specific protein or DNA), angiogenesis inhibitors (thalidomide), anti-apoptotic agents (bryostatin via inhibition of protein C kinase) and cytokines (IL-2, IL-6 and IL-12). [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] This article discusses
Correspondence: Dr HM Lazarus, Department of Medicine, University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland, OH 44106, USA the current status of two other approaches, eg tandem autografts and 'reduced conditioning' ('mini') allogeneic transplants. Table 1 depicts a number of factors shown in some series to favorably affect patient outcome. Many of these parameters are evaluated at diagnosis while a few have been shown to be predictive when used in the pre-transplant setting. The strongest predictor of favorable outcome is the absence of chromosome 13 abnormalities. [22] [23] [24] Abnormalities of chromosome 13 and several translocations are predictors of poor prognosis. [25] [26] [27] [28] [29] When employing routine metaphase karyotyping, only 15% of patients have abnormalities of chromosome 13. More sensitive technologies, such as FISH analysis, however, can detect chromosome 13 abnormalities in over 50% of patients; the significance of using an assay with this level of sensitivity is not known. Our current technologies to detect poor prognostic features have surpassed our current ability to improve the outcome in these high-risk patients.
Prognostic factors
The Arkansas group reported that transplant within the first 12 months from diagnosis is a favorable prognostic factor. 25, 30 In a randomized trial Fermand and colleagues 31 showed that although overall survival between early and late transplant did not differ significantly, patients trans- Table 1 Factors shown in some series to favorably affect multiple myeloma patient outcome Less than 12 months of therapy before transplant Use of non-TBI preparative regimens Age less than 60 years Low serum beta-2 microglobulin Low serum C-reactive protein Non-IgA isotype Low soluble IL-6 receptor No abnormalities of chromosomes 11q and 13 and no translocations Low density marrow angiogenesis Absence of plasmablastic morphology Low plasma cell labeling index Serum creatinine р1 mg/dl Absence of circulating plasma cells in blood stem cell collections Achievement of complete remission planted early, ie before evidence of progression, had a prolonged progression-free survival (39 months vs 13 months) that was associated with an improvement in quality of life. Gertz et al 32 reserved transplant for patients who progressed after four cycles of infusional VAD therapy and 12 cycles of VBMCP. Median progression-free survival and overall survival after transplant were only 11 and 20 months, respectively. These and other clinical data support utilizing high-dose therapy with autologous stem cell transplant earlier in the disease course rather than as salvage therapy at disease progression. The largest study comparing early vs late transplant, however (the North American Intergroup trial, S9321), consisted of over 800 patients but will not be available for analysis until 2003 (R Kyle, personal communication).
The choice of transplant preparative regimen may affect outcome. Harousseau and associates 33 reported the IFM 95 randomized trial comparing melphalan 200 mg/m 2 to melphalan 140 mg/m 2 plus TBI 800 cGy. They observed the TBI regimen to be associated with a higher transplantrelated mortality (5% vs 0%, P ϭ 0.07) but response rates did not differ significantly. At interim analysis, overall survival in the non-TBI group was superior. 34 Desikan et al 35 analyzed historic data involving patients receiving tandem autotransplants using melphalan 200 mg/m 2 . Those who received melphalan 200 mg/m 2 plus cyclophosphamide 120 mg/kg had superior outcome compared to melphalan 140 mg/m 2 plus 850-1020 cGy TBI. Of note, the non-TBI regimen was associated with faster hematopoietic recovery, lower treatment-related mortality and morbidity with an improved overall survival compared to the chemo-radiotherapy regimen. The European Bone Marrow Transplant (EBMT) group conducted a multivariate analysis of prognostic factors and concluded that non-TBI regimens were independently associated with a better survival. 36 In a recent update of over 8000 autotransplants in multiple myeloma patients, Björkstrand et al 37 and the EBMT reported that a non-TBI regimen was more efficacious.
At time of initial diagnosis as well as transplant, the presence of elevated serum beta-2 microglobulin and C-reactive protein are poor prognostic variables. 38, 39 Chemotherapy sensitivity has been identified by both the Arkansas group and the EBMT to be an important prognostic factor. 25, 36 Other less well-accepted factors which portend a poor prognosis include IgA isotype, elevated soluble IL-6 receptor, plasma cell labeling index Ͼ1%, plasmablastic morphology, high-density bone marrow angiogenesis and patient age Ͼ60 years. [40] [41] [42] [43] [44] Siegel and associates 45 demonstrated that patients over age 65 years experience higher early treatment-related mortality than younger patients, although response rates, event-free survival and overall survival did not differ significantly. When high-dose therapy was extended to patients over 70 years, transplant-related mortality was even higher. Melphalan dose-reduction from 200 mg/m 2 to 140 mg/m 2 , on the other hand, reduced treatment-related mortality substantially without a significant reduction in response rates. 46 Palumbo et al 47 studied myeloma patients over age 60 years given two or three (if not in complete remission) sequential cycles of intermediatedose melphalan 100 mg/m 2 supported by autologous hematopoietic stem cell transplant. This group had superior response rates, event-free and overall survival when compared to a historic control population treated with conventional melphalan/prednisone therapy. Finally, the French studies (IFM 90 and IFM 94) indicate that patients over age 60 years have less favorable outcomes after autograft (see below).
Renal insufficiency is often used to exclude patients from autotransplant. Tricot et al 48 showed that pharmacokinetics for high-dose melphalan are similar in patients without renal impairment. On the other hand, treatment-related morbidity and mortality may be increased substantially if other agents are used in the setting of renal insufficiency. Mehta et al 49 conducted a matched-pair analysis of 42 myeloma patients with renal insufficiency (serum creatinine у2 mg/dl) vs 84 patients who had normal renal function. They observed a higher early transplant-related mortality but response rates were similar between groups. The 3-year projected survival was 44% vs 59%, P ϭ 0.15. In a separate analysis, Mehta and co-workers 50 used carboplatin, cyclophosphamide and etoposide and reported that four of six patients with pre-transplant serum creatinine Ͼ1 mg/dl experienced renal failure or death compared to only one of 12 subjects who had a baseline serum creatinine р1 mg/dl. Ballester and associates 51 reported the results of autotransplant after high-dose cyclophosphamide and busulfan in six myeloma patients suffering with renal insufficiency (serum creatinine Ͼ3 mg/dl). Although they noted that there was one transplant-related death, two subjects remained in complete remission more than 28 and 39 months after autograft.
Finally, the presence of monoclonal plasma cells in peripheral blood progenitor cells collections to be used for autotransplant are associated with shortened relapse-free survival. 52 Use of CD34 ϩ cell selection of the peripheral blood stem cell graft, however, has not been associated with improved outcome. [53] [54] [55] [56] [57] [58] These known prognostic factors, and possibly other biologic variables yet to be identified, clearly affect outcome after transplant. Such data suggest that inherent tumor biology significantly influences prognosis and must be considered in planning and interpreting trials that utilize hematopoietic stem cell transplantation. The current IFM 99 study is a risk-based trial utilizing tandem autotransplant with melphalan 140 mg/m 2 followed by melphalan 200 mg/m 2 for low-risk patients (0-1 risk factors, eg elevated serum beta-2 microglobulin or deletion chromosome 13). High-risk patients (elevated serum beta-2 microglobulin as well as deletion chromosome 13) are treated with tandem transplantation with melphalan 200 mg/m 2 followed later by either an allogeneic transplant (non-myeloablative or full-myeloablative) for those patients with HLA-compatible donors, or to a second autotransplant with melphalan 220 mg/m 2 and then randomization to either anti-IL-6 monoclonal antibody or observation.
Tandem transplants
Attainment of a complete remission after autotransplant has been shown to have a significant positive effect on both event-free and overall survival. 1, 25, 30, 37, 59 These data support the conceptual basis for tandem or double autotransplants.
Harousseau et al, 60 Björkstrand et al 61 30 reported the results of tandem autografts as consolidation therapy in a 231-patient 'Total Therapy' nonrandomized trial. Using an intent-to-treat analysis, complete response rates were 26% after first transplant and 38% after second transplant. A total of 165 patients (71%) completed two transplants (151 autografts and 14 allografts); complete remission rate was 41% for those subjects completing the planned tandem transplants. The time interval from first to second transplant ranged from 2.4 to 11.2 (median 4.5) months. The treatment-related mortality was Ͻ1% (two of 195) for the first and 3.6% (six of 165) for the second transplant. All transplant-related mortalities occurred within the first 24 months after transplant. The event-free and overall survival rates were 43 and 68 months, respectively. This group also reported over 1000 consecutive patients (newly diagnosed and previously treated) using a tandem high-dose therapy program. All 1000 patients received melphalan 200 mg/m 2 as the first high-dose chemotherapy, and 760 (76%) patients received a tandem transplant. Preparative regimens for the second transplant included melphalan 200 mg/m 2 , melphalan 140 mg/m 2 ϩ 850-1020 cGy TBI, as well as other approaches including allogeneic transplant in 100 patients. They demonstrated a complete remission rate of 44% (median duration 2.4 years) and projected 5-year event-free and overall survival rates of 25% and 40%, respectively. 25 The transplant-related mortality was 2.7% for first transplant and 4.8% for second transplant. This result compares favorably with historic controls treated with conventional therapy in which the 5-year survival is approximately 25%. Huijgens and associates 66 recently reported a series in which 90 patients underwent a first autotransplant using melphalan 140 mg/m 2 , followed in 49 patients by second autograft using busulfan 16 mg/kg and cyclophosphamide 120 mg/m 2 . Transplant-related mortality was 3% with the first and 8% with the second transplant. These investigators reported the data in aggregate, ie 19 of 90 patients attained complete remission. Overall survival was 49 months for single transplant and 84 months for tandem transplant.
Four current prospective studies are being conducted to evaluate sequential high-dose therapy vs a single high-dose therapy strategy. In a preliminary communication, Tosi and colleagues 63 reported a multi-center, randomized trial comparing single to tandem transplant in 204 untreated patients (median follow-up 26 months; projected accrual 320 patients). Initial therapy consisted of four cycles of infusional VAD and stem cell mobilization after cyclophosphamide 7 g/m 2 and G-CSF. A first autotransplant used melphalan 200 mg/m 2 while melphalan 120 mg/m 2 and busulfan 12 mg/kg comprised the second transplant regimen. At the interim analysis, 85% of patients completed initial therapy and first transplant, while only 65% of patients assigned to a second transplant completed the prescribed therapy. There was no difference in response rates between the two groups (31% vs 37%). Using an intent-to-treat analysis, at 2 years there was no difference in event-free Bone Marrow Transplantation survival and overall survival (82% vs 84%). However, there was improvement in event-free survival at a 5-month landmark analysis of patients who completed a second transplant. 67 Fermand and colleagues 68 reported data on 193 patients of a planned 230 patient study (median follow-up 27 months). They utilized three cycles of infusional VAD, mobilization chemotherapy with cyclophosphamide 4 g/m 2 , a first transplant using carmustine, etoposide, melphalan 140 mg/m 2 , cyclophosphamide 60 mg/kg and total body irradiation (1200 cGy) for patients randomized to a single transplant. Patients randomized to tandem transplant received melphalan 140 mg/m 2 with autotransplant followed 2-3 months later by melphalan 140 mg/m 2 , etoposide 30 mg/kg and total body irradiation (1200 cGy) with a second autograft. In addition, patients were randomized to CD34 ϩ selection of the autograft stem cell collection using an Isolex 300 (Nexell, Irvine, CA, USA) vs infusion of unselected stem cells. Using an intent-to-treat analysis, to date, there have been no differences in transplant-related mortality, response rates, event-free or overall survival. Furthermore, no advantage has been demonstrated for in vitro CD34
ϩ selection of the autograft collection before infusion. In the CD34 ϩ selected group, however, there was a delay in immunological recovery resulting in an increased in serious infections. Segeren and co-workers 70 evaluated a dose-intensive regimen compared to a dose-intensive regimen followed by high-dose therapy with an autologous transplant. All patients received VAD for three to four cycles, and stem cell mobilization using cyclophosphamide 4 g/m 2 . Patients were then randomized to receive either dose-intensive therapy consisting of two cycles of melphalan 70 mg/m 2 (4-8 weeks apart) without stem cell support, or the same regimen followed by high-dose cyclophosphamide 120 mg/kg plus TBI with autologous stem cell support. Two hundred and fifty-five of a planned 453 patient enrollment and randomization have been completed. Presently, no differences in overall response rates, eventfree or overall survival have been detected between the dose-intensive group (two cycles of melphalan 70 mg/m 2 ) and the dose-intensive/high-dose therapy group.
Attal and colleagues 64 for the Inter Groupe Français du Myélome (IFM) completed a randomized trial consisting of 402 patients comparing single vs tandem transplant after initial therapy using three to four cycles of infusional VAD (IFM 94). Patients were randomized to either a single transplant utilizing melphalan 140 mg/m 2 with total body irradiaton (800 cGy) or a double transplant utilizing melphalan 140 mg/m 2 followed by melphalan 140 mg/m 2 with total body irradiation (800 cGy). All patients were to receive interferon post transplant. The preliminary results showed no difference in overall survival between groups at a median follow-up of 4 years, although patients with low serum beta-2 microglobulin in the tandem transplant group had a superior outcome. For patients that survived for more than 3 years after diagnosis, tandem transplants were found to significantly improve 5-year survival (70% vs 80% P ϭ 0.01). In the most recent subgroup analysis, patients receiving tandem transplants with peripheral blood stem cell support had a superior outcome to patients receiving tandem bone marrow transplants or single stem cell or bone marrow transplants. 69 This group had higher response rates and improved event-free and overall survivals.
These results are in stark contrast to two parallel studies within the IFM 94 trial 64,69 (Table 3) . There was no difference in patient outcome comparing bone marrow to peripheral blood stem cells as an independent variable. Furthermore, response rate, event-free survival and overall survival rates did not differ in a non-randomized subgroup of 729 patients that were evaluated comparing CD34 ϩ selected vs unselected peripheral blood stem cells as graft source. What is unexplained is why tandem bone marrow transplants as a source of hematopoietic stem cells should result in an inferior outcome in both response rates and survival compared to tandem peripheral blood stem cell transplants. Although it is likely that there is a higher tumor cell concentration in the bone marrow compared to the peripheral blood, studies utilizing CD34 ϩ selection, that provide up to five log depletion of tumor cells, fail to show an improvement in event-free survival or overall survival.
52,55-58 Similar findings with single transplant failed to show a response or survival advantage for CD34 ϩ selection.
53,54
Finally, Björkstrand et al 37 completed a retrospective analysis of the EBMT Registry database. Restricting the review to chemotherapy-responsive patients transplanted since 1991, they compared 441 subjects who received double transplants to 1380 patients who received a single transplant. While a significant difference in progressionfree survival was observed, overall survival did not differ (single: 67 months; double 85 months; P ϭ 0.1).
Reece and associates 65 and Lemoli et al 55 each reported a small series using tandem high-dose autografts. Both studies showed acceptable toxicity but follow-up was short. The focus of the latter trial 55 was the safety and efficacy of CD34 ϩ cell selection of the autograft blood stem cell collection in vitro.
There appears to be an inherent selection bias with respect to which patients are referred for and subsequently undergo tandem transplants, particularly in the United States. As noted above, many biologic factors can greatly influence outcome. In most series, time to the second transplant is greater than the planned 3 months. Furthermore, the majority of studies reserve a second transplant only for responding patients. Many unanswered questions include identifying which patients should have tandem transplants (good prognosis vs poor prognosis patients), timing (immediately or at time of disease progression), and use of tandem transplants in patients who achieved complete remission after first transplant. At present, tandem transplants cannot be considered standard of care for multiple myeloma.
Allogeneic transplant
Allogeneic hematopoietic stem cell transplantation is an option for only a minority of patients (5-10%) who have
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HLA-compatible donors and are under age 60 years. Molecular remissions can be achieved frequently with allogeneic hematopoietic stem cell transplantation but rarely after single autografts. 71, 72 Achievement of molecular remission does translate into improved outcome. 71, 73 Allogeneic transplants have an obvious advantage over autografts because the graft is tumor-free and there is the potential benefit of a graft-versus-myeloma effect.
71,74-80 A survival advantage, however, has not been demonstrated for allografts due to a higher treatment-related mortality; the higher complete remission rate observed with allograft does not compensate. 74, 75, 81, 82 In fact, overall survival after autograft was 34 months compared to 18 months in retrospective, case-matched analysis of 178 patients reported to the EBMT. 75 Six studies enrolling 52 to 198 patients showed that treatment-related mortality varied from 8 to 57% (median: 41%); 71, 72, 74, 75, 82, 83 five of six trials had a treatment-related mortality rate of at least 18%. The exception to these results is a 54-patient trial reported by Schlossman and co-workers, 84 in which the CD6 depletion technique was utilized and resulted in an early 8% treatment-related mortality. The allogeneic transplant arm of the randomized, phase III, National Cancer Institute-intergroup trial S9321 was closed prematurely due to a 41% treatment-related mortality rate. The most recent update of the EBMT data indicates that the transplant-related mortality has improved over the most recent 5 years (1994-1998) compared to the previous 10 years (1983-1993), 20% vs 40%. 2 The authors indicate that the improvement in survival is due to less infectious complications and decrease in interstitial pneumonitis. Zamagni et al 85 also reported a decrease in mortality in Italy over the most recent 5 years (15% vs 38%). Several factors accounted for the improved survival: earlier timing, better patient selection and improved supportive care. Unfortunately, even with better supportive care measures, the complete remission rates have not improved over time. 2, 38 The largest published allogeneic transplant data have been reported by the European Blood and Bone Marrow Transplant Registry (EBMT). 86 They reported a 51% complete remission rate in 266 patients. Overall treatmentrelated mortality rate was approximately 40% and the actuarial survivals were 30% at 4 years and 20% at 10 years. An update of the EBMT database in over 600 patients showed complete remission rates of 15% and a transplant-related mortality (1994-1998 data) of 20%. 2 Although the relapse rate after the first 2 years is small, late relapses continue to occur. The largest single institution studies have been reported from the Seattle 83 and Arkansas 82 groups; in both trials a number of patients previously underwent and failed an autograft. Bensinger and colleagues 83 reported a 36% complete remission rate in 106 multiple myeloma patients given allogeneic sibling donor marrow grafts. However, the transplant-related mortality rate was 50% at 100 days and additional 7% of patients died within the first year from transplant-related complications. The actuarial probabilities of overall and progression-free survival were 0.23 and 0.16 at 4 years after transplant. Mehta and associates 82 reported the results of 97 patients undergoing allogeneic transplant; 80 subjects received sibling-donor grafts, while 17 were given unrelated donor grafts. Although 19 patients remained in an apparent continuous complete remission 3-61 months after transplant, 3-year probability of treatmentrelated mortality was 0.54. Overall and event-free survivals at 3 years are 0.17 and 0.11, respectively.
Alternative donor transplants similarly have been associated with poor outcomes. Ballen et al 87 reported the National Marrow Donor Program experience in 71 myeloma patients receiving unrelated donor grafts. Although 43 (55%) patients achieved a complete remission after transplant, the 2-year cumulative incidence for relapse was estimated to be 33% and the 100-day treatment-related mortality was 41%. The Kaplan-Meier estimate for overall survival at 5 year after transplant was only 17%. Bensinger and colleagues at the Fred Hutchinson Cancer Research Center 88 reported equally poor results using alternate donor transplants.
Poor patient outcome using allogeneic transplant may reflect patient selection, ie these procedures are often performed in heavily pre-treated patients who frequently have failed an autologous transplant. On the other hand, in the course of the North American Intergroup trial (S9321), allogeneic transplantation was performed early, after four cycles of VAD and high-dose cyclophosphamide (4.5 g/m 2 ). This arm of the study, which assigned allograft to patients under age 55 years who had an HLA-identical sibling donor, was closed prematurely when the transplantrelated mortality reached 41% after the first 36 patients had undergone transplant (R Kyle, personal communication).
Case-matched comparative studies comparing allogeneic and autologous transplant all showed superior outcomes with autologous transplant due to the higher transplantrelated mortality associated with allogeneic transplant. 2, 74, 81, 89 Given the high treatment-related mortality rate and the uncertainty of future cures, full myeloablative allogeneic transplants cannot be recommended for multiple myeloma patients.
Non-myeloablative transplants
A significant component of the curative potential of allogeneic transplants is the infusion of alloreactive T lymphocytes against host tumor cells. This effect has been well-appreciated in B cell malignancies and chronic myeloid leukemia. The most compelling clinical evidence to support this concept are the observations of: (1) higher relapse rates in syngeneic and T cell-depleted transplants; (2) reduced risk of relapse in patients who develop GVHD after allograft; and (3) the efficacy of donor lymphocyte infusions (DLI) to induce complete remission in many patients with cytogenetic (rather than clinically overt) relapse. The effectiveness of DLI in inducing remissions in recurrent disease after allogeneic transplant has been demonstrated in most hematologic malignancies, and some solid tumors, with various success rates ranging from approximately 10-15% in acute lymphoblastic leukemia to 70-80% in chronic myelogenous leukemia. 90 This principle has also been proven in disease relapse following unrelated donor transplants. 91 Immunoreactive T lymphocytes can induce clinical remissions in myeloma patients who have relapsed after allogeneic transplantation. 77, 78, 80, [92] [93] [94] In the largest trial demonstrating the efficacy of DLI, Lokhorst et al 77 noted that 14 of 27 relapsed patients responded to DLI, including six subjects who attained a complete remission. Median survival for the entire group was 18 months; five patients remain in continuous complete remission a median of 31 months after receiving this approach. Acute GVHD grade у2 occurred in 15 (56%) patients, while seven (26%) patients developed chronic GVHD (four limited; three extensive). Similar findings were updated by this group reporting data on 39 patients receiving 68 DLI. 95 Graftversus host disease remains problematic after DLI; acute GVHD and chronic GVHD were observed in 47% and 33% of patients, respectively. Salama et al 96 conducted a review of DLI in myeloma. They presented data collected from 25 patients treated at 15 centers. Complete remissions were noted in two of 22 patients receiving DLI alone and in three patients receiving DLI after chemotherapy. Nine patients received additional DLI due to the absence of complete response and two complete and three partial responses were observed. Thirteen of 25 evaluable patients developed acute GVHD and 11 of 21 subjects developed chronic GVHD. Seven patients remained in complete remission (four for at least 1 year, three less than 1 year); three subjects have responded but follow-up is less than 1 year. In both of these studies, GVHD remains a significant toxicity. To obviate one drawback of GVHD, some investigators have transduced donor lymphocytes with the suicide gene viral thymidine kinase. 97, 98 Such cells can be eliminated in vivo with systemic administration of antivirals at first sign of GVHD. Alternatively, Alyea and co-workers 93 infused a purified DLI graft predominantly of CD4 ϩ lymphocytes after depleting CD8 ϩ lymphocytes. Treatment-related mortality was only 3% and five of six relapsed myeloma patients responded to this maneuver.
Due to the excessively high transplant-related mortality associated with conventional allogeneic transplants and the efficacy of immunoreactive donor T lymphocytes, an emerging trend is to utilize non-myeloablative or reducedconditioning transplants ('mini-transplants') for a number of hematologic malignancies including multiple myeloma. 99 The basis of the 'mini-transplant' is to provide sufficient immune suppression to allow donor engraftment and subsequent graft-versus-tumor effect. Additionally, nonmyeloablative stem cell transplants are attractive since patients who are not thought to be candidates for conventional allografts due to advanced age, co-morbid illness, or extensive previous therapy (including a prior autograft) are eligible for this type of transplant.
Badros et al 100 have published the Arkansas group's experience in non-myeloablative transplants for myeloma. They utilized a preparative regimen of melphalan 100 mg/m 2 followed by allogeneic peripheral blood stem cell transplants in 16 heavily pre-treated myeloma patients: 10 refractory disease, four responsive relapse and two patients in near-complete remission. At a median of 1 year followup, sustained complete remissions were achieved in five patients while four attained partial remission. Although there were no transplant-related deaths in the first 100 days, acute GVHD developed in 10 patients and chronic GVHD in seven patients; the late transplant-related mortality was 19%. These data were updated at the International Myeloma Workshop by Barlogie et al. 101 Thirty-one patients have now received non-myeloablative transplants: the complete response rate was 61% including seven of 17 patients with resistant disease. The transplant-related mortality, however, remained unacceptably high at 33%. Table 4 depicts the results of several non-myeloablative transplant studies involving multiple myeloma patients. [100] [101] [102] [103] [104] [105] [106] [107] [108] Lalancette et al 102 reported results from 50 patients, in whom all demonstrated evidence of donor engraftment (20 of 27 evaluable patients achieved 95% donor engraftment). Complete remissions were attained in 16 patients, although transplant-related mortality at 1 year was 32%. The actuarial survival rates at 1 and 2 years after transplant were 54% and 40%, respectively. When the patients were stratified into 'good' and 'poor' risk groups (good-risk defined as first complete remission, first or second partial remission), the overall survival and transplant-related mortality in the good risk group was 83% and 13%, respect- Table 4 Non-myeloablative transplants for multiple myeloma Bone Marrow Transplantation ively, compared to 25% and 67%, respectively, in the poor risk group. The other series shown included small numbers of patients and short follow-up; often, this therapy was planned to follow an autograft procedure. As anticipated, acute and chronic GVHD accompany the procedure and contribute to treatment-related mortality. Indeed, both acute and chronic GVHD appear to be observed at a higher incidence in myeloma patients following non-myeloablative transplant compared to conventional allogeneic transplant. While rates are lower than that associated with conventional allogeneic transplants, the treatment-related mortality due to 'mini-transplant' remains significant ranging from 13 to 67%. The incidence of acute and chronic GVHD was 67% and 47%, respectively. Non-myeloablative transplants are associated with considerable toxicity and treatment-related mortality rates may approach those observed with conventional allografts. Nonetheless, the Seattle group recently reported an intriguing pilot trial of autologous transplant (melphalan 200 mg/m 2 ) followed by non-myeloablative allogeneic transplant (Ref. 105 and W Bensinger, personal communication). This appealing concept utilizes the autologous transplant to maximize tumor cytoreduction and provide a low tumor burden to enable donor T cells to exert a graft-versus-myeloma effect to eradicate minimal residual disease. Thirty-two patients have completed the planned tandem transplant procedures: the complete response rate was 53%; transplant-related mortality 16%. Three patients have received DLI for persistent disease: one subject has achieved a complete remission and two have attained partial responses. The incidences of acute and chronic GVHD were 39% and 57%, respectively. The median follow-up, however, is short (2.4 months). The Eastern Cooperative Oncology Group has initiated a multi-institutional protocol (E4A98) that utilizes a similar approach.
Conclusions
Multiple myeloma remains a challenge for the hematologist/ oncologist due to the low proliferative rate of the clonal plasma cells. Neither single nor tandem autografts appear to provide sufficient anti-tumor benefit and are not curative. Tandem transplants have been compared to single autografts in three randomized trials; none of these studied have been scrutinized for peer-review publication. It remains uncertain if there is a definite disease-free or overall survival benefit for tandem transplantation. Use of conventional myeloablative allografts is questionable due to excessive transplant-related mortality. Reduced-conditioning allografts are being explored as an intriguing alternative. Transplant-related morbidity (chronic GVHD) and mortality associated with these non-myeloablative approaches, however, remains a continued cause for concern.
A number of factors influence patient outcome in multiple myeloma and large, randomized trials are necessary to establish the benefit of these two approaches in order to discount the potential influence of patient selection. Ultimately, a treatment strategy that combines several therapies, including autotransplant (for maximal cytoreduction), immunoablation by alloreactive T lymphocytes (non-myeloablative therapy with DLI) and long-term immunomodulation to treat minimal residual disease and prevent disease recurrence (angiogenesis inhibitors, cytokines and vaccines) may provide the optimal control and potential cure for this challenging disease. microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. 
